Relieves bronchospasm. ANDA 212197, held by Quagen Pharmaceuticals. Albuterol Sulfate.
As of Nov 18, 2026, ANDA 212197 (Albuterol Sulfate), held by Quagen Pharmaceuticals, was first approved by FDA on Sep 6, 2019, with 0 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Albuterol Sulfate Syrup is indicated for the relief of bronchospasm in adults and children 2 years of age and older with reversible obstructive airway disease.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 6, 2019 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Albuterol SulfateEQ 2MG BASE/5ML · syrup;oral | Albuterol Sulfate | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters